22 December 2017 - The objective of this study was to estimate the expected incremental cost per quality-adjusted life-year (QALY) gained of increased government health expenditure as an empirical estimate of the average opportunity costs of decisions to fund new health technologies. 

Empirical top-down approaches were used to estimate the QALY effects of government health expenditure with respect to reduced mortality and morbidity.

The base-case reference ICER was estimated at AUD28,033 per QALY gained. Parametric uncertainty associated with the estimation of mortality- and morbidity-related QALYs generated a 95% confidence interval AUD20,758-37,667.

Read PharmacoEconomics article